Design and Evaluation of Diclofenac Sodium MegaloporousMatrix System Aimed forColonic Drug Delivery Design of a matrix system for diclofenac delivery
Iranian Journal of Pharmaceutical Sciences,
Vol. 3 No. 1 (2007),
15 Dey 2007
,
Page 1-12
https://doi.org/10.22037/ijps.v3.40327
Abstract
Megaloporous controlled release tablets of diclofenac sodium (DS) were preparedwith two kinds of granules. One of them is the restraining-phase matrix granule(RMG) and it controls the release rate of the drug. The other one is the solublehousing-phase matrix granule (HMG) and controls liquid penetration into thesystem. Carnauba wax and Eudragit L100 polymers were used to constitute therestraining and housing matrix phases, respectively. The prepared tablets wereevaluated for various parameters. In vitrodrug release study was carried out insimulated gastric fluid (pH 1.2) for the first 2 h and in phosphate buffer (pH 7.2)for the next 10 h following USP25 paddle method. Two independent modelmethods, AUC and Lin Ju and Liaw's difference factor (ƒ1) and similarity factor (ƒ2)were used to compare various dissolution profiles. The fabricated megaloporousmatrix tablets released only 3 to 5% of DS in pH 1.2 depending on the proportionof carnauba wax used in the RMG. Increase in polymer content/hardness value ofthe tablet resulted in a significant decrease in AUC0-2h and AUC2-12h values . Thef1and f2analysis also confirms the discrimination between corresponding dissolutionpairs. The dissolution profiles of an ideal matrix formulation containing 15.77%carnauba wax and 6.76% Eudragit L100 was found to be comparable with thereference product (Voveran®SR) and theoretical release profile. The drug releasefrom all fabricated products and reference product followed better Higuchi modelthan the zero order and first order kinetic models. Ritger-Peppas model analysisindicated that the DS release followed non-Fickian transport mechanism. From theabove analysis, it is evident that the release mechanism of DS from matrix tabletis influenced by both hardness and polymer contents. The stability profiles indicatethat the physico-chemical properties of the tablets are not affected on storage at 45°C/75% RH up to 6 months.
- Colonic targeting
- Diclofenac sodium
- Megaloporous matrix tablets
- Release kinetics
- Sustained release
How to Cite
References
[3]Bjarnasson I, Fehilly B, Smethurst P, Menzies IS,Levi AJ. Importance of local versus systemiceffects of non-steroidal anti-inflammatory drugsin increasing small intestinal permeability in man.Gut 1991; 32: 275-7.
[4]Gleiter CH, Antonin KH, Bieck P, Godbillon J,Schonleber W, Malchow H. Colonoscopy in theinvestigation of drug absorption in healthyvolunteers. Gastrointest Endosc1985; 31: 71-3.
[5]Schacht E, Gevaert A, Kenawy ER, Molly K,Verstraete W, Adriaensens P, Carleer R, Gelan T.Polymers for colon specific drug delivery.JControl Rel1996; 39: 327-38.
[6]Khan MZI, Prebeg Z, Kurjakovic N. ApH-dependent colon targeted oral drug deliverysystem using methacrylic acid copolymers, I:manipulation of drug release using eudragit L100-55 and Eudragit S100 combinations. J Control Rel1999; 58: 215-22.
[7]Fukui E, Miyamura N, Uemura K, KobayashiM. Preparation of enteric coated timed-releasepress-coated tablets and evaluation of theirfunction by in vitroand in vivotests for colontargeting.Int J Pharm2000; 204: 7-15.
[8]Prasad YVR, Krishnaiah YSR, Satyanarayana S.In vitroevaluation of guar gum as a carrier forcolon-specific drug delivery. J Conrol Rel1998;58: 281-7.
[9]Karasulu HY, Ertan G. Different geometricshaped hydrogel theophylline tablets: Statisticalapproach for estimating drug release. ILFarmaco2002; 57: 939-45.
[10]Fassihi AR. Continuous matrix formation forcontrolled drug release: Compression of isotropicpolymeric system. Int J Pharm1986; 34: 169-72.
[11]Ozgüney I, Ertan G, Güneri T. Dissolution char-acteristics of megaloporous tablets prepared withtwo kinds of matrix granules. ILFarmaco2004;59: 549-55.
[12]Haan PD, Lerk CF. Parameters affecting the rateof exposure of the drug containing phase in themegaloporous system. Acta Pharm Technol1988;34: 106-7.
[13]Kuttel S, Mezei J, Racz I. Formulation of acontrolled-release iron preparation. Pharm Ind1990; 52: 121-3.
[14]Shah SS, Kulkarni MG, Mashelkar RA. pHdependent zero-order release from glassy hydrogels: Penetration vs. diffusion controlled. JControl Rel1991; 15: 221-32.
[15]Indian pharmacopoeia. Vol II. New Delhi:Controller of Publications, Government of India,1996.
[16]The United States Pharmacopoeial Convention,USP25-NF-20. Rockville, 2002.
[17]Benet LZ, Williams RL. Design and optimizationof dosage regimens: Pharmacokinetic data. In:Goodman A, Gilman A, Rall TW, Nies AS, TaylorP, (editors). Goodman and Gillman's the pharma-cological basis of therapeutics. New York:Pergamon Press, 1990; pp.1650-736.
[18]Benson MD, Aldo-Benson M, Brandt KD.Synovial fluid concentrations of diclofenac inpatients with rheumatoid arthritis or osteoarthritis.Semin Arthritis Rheum1985; 15: 65-7.
[19]Krüger-Thiemer E, Eriksen SP. Mathematicalmodel of sustained release preparations and itsanalysis. J Pharm Sci 1966; 55: 1249-53.
[20]Robinson JR, Eriksen SP. Theoretical approach tosustained-release multiple-dose therapy:Noncumulative attainment of desired blood level.J Pharm Sci1970; 59: 1796-800.
[21]Lordi NG. Sustained release dosage forms. In:Lachman L, Lieberman HA, Kanig JL, (editors).The theory and practice of industrial pharmacy.Bombay: Varghese Publishing House, 1990; pp.430-56.
[22]Gibaldi M. Biopharmaceutics and clinical phar-macokinetics. Philadelphia: Lea and Febiger,1991; pp. 377-8.
[23]Lin Ju H, Liaw SJ. On the assessment of similarityof drug dissolution profiles: Asimulation study.Drug Inf J1997; 31: 1273-89.
[24]Banakar UV. Dissolution & Bioavailability. In:Banakar UV, (editor). Pharmaceutical dissolutiontesting. New York: Marcel Dekker INC, 1992; pp.347-84.
[25]Duncan BD. Multiple range tests for correlatedand heteroscedastic means.Biometrics1957; 13:359-64.
[26]Bamba M, Puisieux JP, Marty JP, Carstensen JT.Physical model for release of drug from gelforming sustained release preparations. Int JPharm 1979; 3: 87-92.
[27]Higuchi T. Mechanism of sustained-actionmedication: Theoretical analysis of rate of releaseof solid drugs dispersed in solid matrices. J PharmSci1963; 52: 1145-9.
[28]Harland RS, Gazzaniga A, Sangalli ME, ColomboP, Peppas NA. Drug-polymer matrix swellingand dissolution. Pharm Res1988; 5: 488-94.
[29]Carstensen JT. Solid state stability. In: CarstensenJT, Rhodes CT, (editors). Drug stability:Principles and practices. New York: MarcelDekker INC, 2000; pp. 145-89.
[30]Tarimci NM, Agabeyoglu I. Studies on sustainedrelease. III. Matrix granules of sulfamethizole.Drug Dev Ind Pharm1985; 11: 2043-56.
[31]Billa N, Yuen KH, Peh KK. Diclofenac releasefrom eudragit containing matrices and effect ofthermal treatment. Drug Dev Ind Pharm1998; 24:45-50.
[32]Shlieout G, Zessin G. Investigation ofethylcellulose as a matrix former and a newmethod to regard and evaluate the compactiondata. Drug Dev Ind Pharm1996; 22: 313-9.
- Abstract Viewed: 87 times
- IJPS_Volume 3_Issue 1_Pages 1-12 Downloaded: 17 times